Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
Emma Nolan, Peter Savas, Antonia N. Policheni, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 393
Open Access | Times Cited: 250

Showing 1-25 of 250 citing articles:

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
Peter Savas, Balaji Virassamy, Chengzhong Ye, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 986-993
Closed Access | Times Cited: 845
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic, Kevin Litchfield, Hang Xu, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 8, pp. 1009-1021
Open Access | Times Cited: 826
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi, Damien Drubay, Sylvia Adams, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 7, pp. 559-569
Open Access | Times Cited: 657
In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Chao Wang, Jinqiang Wang, Xudong Zhang, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 429
Open Access | Times Cited: 515
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 483
Recent advances in therapeutic strategies for triple-negative breast cancer
Yun Li, Huajun Zhang, Yulia Merkher, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 474
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer
Daniel P. Hollern, Nuo Xu, Aatish Thennavan, et al.
Cell (2019) Vol. 179, Iss. 5, pp. 1191-1206.e21
Open Access | Times Cited: 396
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson, Chaitanya Bandlamudi, Michael L. Cheng, et al.
Nature (2019) Vol. 571, Iss. 7766, pp. 576-579
Open Access | Times Cited: 355
Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation
Xin Liang, Xinyu Ye, Chao Wang, et al.
Journal of Controlled Release (2019) Vol. 296, pp. 150-161
Closed Access | Times Cited: 351
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Alice Lee, M.B.A. Djamgoz
Cancer Treatment Reviews (2017) Vol. 62, pp. 110-122
Closed Access | Times Cited: 323
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra, Giulia Viale, Giuseppe Curigliano
BMC Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 323
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer
Chun-Chin Chen, Weiran Feng, Pei Xin Lim, et al.
Annual Review of Cancer Biology (2017) Vol. 2, Iss. 1, pp. 313-336
Open Access | Times Cited: 286
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Matteo Berti, David Cortez, Massimo Lopes
Nature Reviews Molecular Cell Biology (2020) Vol. 21, Iss. 10, pp. 633-651
Closed Access | Times Cited: 279
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
Debangshu Samanta, Youngrok Park, Xuhao Ni, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 6
Open Access | Times Cited: 265
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome
Gil Friedman, Oshrat Levi-Galibov, Eyal David, et al.
Nature Cancer (2020) Vol. 1, Iss. 7, pp. 692-708
Open Access | Times Cited: 248
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 11, pp. 701-717
Closed Access | Times Cited: 216
Recent therapeutic trends and promising targets in triple negative breast cancer
Soo‐Yeon Hwang, Seojeong Park, Youngjoo Kwon
Pharmacology & Therapeutics (2019) Vol. 199, pp. 30-57
Open Access | Times Cited: 206
Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
Matteo Santoni, Emanuela Romagnoli, Tiziana Saladino, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2017) Vol. 1869, Iss. 1, pp. 78-84
Closed Access | Times Cited: 203
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, et al.
Cancers (2019) Vol. 11, Iss. 7, pp. 1033-1033
Open Access | Times Cited: 194
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
Anita K. Mehta, Emily Cheney, Christina Hartl, et al.
Nature Cancer (2020) Vol. 2, Iss. 1, pp. 66-82
Open Access | Times Cited: 192
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross Stewart, Patrick G. Pilié, Timothy A. Yap
Cancer Research (2018) Vol. 78, Iss. 24, pp. 6717-6725
Open Access | Times Cited: 190
The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
Jennifer Ma, Jeremy Setton, Nancy Y. Lee, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 183
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud, Antoîne Italiano
Cancers (2020) Vol. 12, Iss. 6, pp. 1502-1502
Open Access | Times Cited: 183
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Zhengyan Kan, Ying Ding, Jin-Ho Kim, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 164
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein, Chirag Krishna, Xiaoxiao Ma, et al.
Nature Cancer (2020) Vol. 1, Iss. 12, pp. 1188-1203
Open Access | Times Cited: 156
Page 1 - Next Page

Scroll to top